| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ... Jama 313 (19), 1924-1938, 2015 | 1633 | 2015 |
| The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers N Mattsson, U Andreasson, S Persson, H Arai, SD Batish, S Bernardini, ... Alzheimer's & Dementia 7 (4), 386-395. e6, 2011 | 438 | 2011 |
| CSF biomarker variability in the Alzheimer's Association quality control program N Mattsson, U Andreasson, S Persson, MC Carrillo, S Collins, S Chalbot, ... Alzheimer's & Dementia 9 (3), 251-261, 2013 | 406 | 2013 |
| Neurological manifestations of long-COVID syndrome: a narrative review MI Stefanou, L Palaiodimou, E Bakola, N Smyrnis, M Papadopoulou, ... Therapeutic advances in chronic disease 13, 20406223221076890, 2022 | 221 | 2022 |
| Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? E Kapaki, K Kilidireas, GP Paraskevas, M Michalopoulou, E Patsouris Journal of Neurology, Neurosurgery & Psychiatry 71 (3), 401-403, 2001 | 184 | 2001 |
| Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia WJ Jansen, R Ossenkoppele, BM Tijms, AM Fagan, O Hansson, ... JAMA psychiatry 75 (1), 84-95, 2018 | 180 | 2018 |
| Cerebrospinal fluid tau, phospho‐tau181 and β‐amyloid1−42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease EN Kapaki, GP Paraskevas, NG Tzerakis, C Sfagos, A Seretis, ... European journal of neurology 14 (2), 168-173, 2007 | 161 | 2007 |
| Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ... JAMA neurology 79 (3), 228-243, 2022 | 150 | 2022 |
| Circulating interleukin‐15 and RANTES chemokine in Parkinson’s disease M Rentzos, C Nikolaou, E Andreadou, GP Paraskevas, A Rombos, ... Acta Neurologica Scandinavica 116 (6), 374-379, 2007 | 145 | 2007 |
| Update on vascular cognitive impairment associated with subcortical small-vessel disease A Wallin, GC Román, M Esiri, P Kettunen, J Svensson, GP Paraskevas, ... Journal of Alzheimer's Disease 62 (3), 1417-1441, 2018 | 134 | 2018 |
| Circulating interleukin‐10 and interleukin‐12 in Parkinson’s disease M Rentzos, C Nikolaou, E Andreadou, GP Paraskevas, A Rombos, ... Acta Neurologica Scandinavica 119 (5), 332-337, 2009 | 118 | 2009 |
| Neurofilament ELISA validation A Petzold, A Altintas, L Andreoni, A Bartos, A Berthele, MA Blankenstein, ... Journal of immunological methods 352 (1-2), 23-31, 2010 | 115 | 2010 |
| CSF tau protein and β‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population E Kapaki, GP Paraskevas, I Zalonis, C Zournas European Journal of Neurology 10 (2), 119-128, 2003 | 111 | 2003 |
| The stroop effect in Greek healthy population: normative data for the Stroop Neuropsychological Screening Test I Zalonis, F Christidi, A Bonakis, E Kararizou, NI Triantafyllou, ... Archives of Clinical Neuropsychology 24 (1), 81-88, 2009 | 109 | 2009 |
| Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease-A consensus report A Wallin, E Kapaki, M Boban, S Engelborghs, DM Hermann, B Huisa, ... BMC neurology 17, 1-12, 2017 | 105 | 2017 |
| Increased cerebrospinal fluid tau protein in multiple sclerosis E Kapaki, GP Paraskevas, M Michalopoulou, K Kilidireas European neurology 43 (4), 228-232, 2000 | 105 | 2000 |
| Corticobasal degeneration and corticobasal syndrome: A review VC Constantinides, GP Paraskevas, PG Paraskevas, L Stefanis, E Kapaki Clinical Parkinsonism & Related Disorders 1, 66-71, 2019 | 90 | 2019 |
| The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease E Kapaki, GP Paraskevas, E Emmanouilidou, K Vekrellis PloS one 8 (11), e81654, 2013 | 87 | 2013 |
| Plasma alpha-synuclein levels in patients with Parkinson’s disease: a systematic review and meta-analysis A Bougea, L Stefanis, GP Paraskevas, E Emmanouilidou, K Vekrelis, ... Neurological sciences 40, 929-938, 2019 | 78 | 2019 |
| Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration E Kapaki, GP Paraskevas, SG Papageorgiou, A Bonakis, N Kalfakis, ... Alzheimer Disease & Associated Disorders 22 (1), 47-53, 2008 | 72 | 2008 |
